Novo Nordisk | NVO - Betriebsaufwand





Betriebsaufwand Veränderung Datum
ANI Pharmaceuticals USD 637.11M 39.9M 2026-09
Aurora Cannabis CAD 76.28M 28.24M 2026-06
Bausch Health Companies USD 1.95B 128M 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Canopy Growth CAD 98.74M 23K 2026-06
Corcept Therapeutics USD 225.75M 10.9M 2026-09
Drreddys Laboratories INR 73.9B 431M 2026-09
Eli Lilly USD 10.52B 496M 2026-06
GlaxoSmithKline GBP 6.03B 227M 2026-09
Merck USD 10.75B 5.02B 2026-09
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Novartis USD 9.88B 325M 2026-09
Novo Nordisk DKK 44.73B 7.52B 2026-06
Novo Nordisk DKK 6.96B 30.25B 2026-06
Pacira USD 1.18B 995.96M 2026-09
Perrigo USD 961.4M 670.9M 2026-09
Phibro Animal Health USD 417.67M 1.04B 2026-09
Prestige Brands USD 213.19M 7.06M 2026-06
Sanofi EUR 10.51B 598M 2026-09
Supernus Pharmaceuticals USD 1.06B 31.25M 2026-09
Zoetis USD 3.3B 155M 2026-09